Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 139

1.

Tiered application of the neutral red release and EpiOcular™ assays for evaluating the eye irritation potential of agrochemical formulations.

Settivari RS, Amado RA, Corvaro M, Visconti NR, Kan L, Carney EW, Boverhof DR, Gehen SC.

Regul Toxicol Pharmacol. 2016 Nov;81:407-420. doi: 10.1016/j.yrtph.2016.09.028.

PMID:
27693708
2.

Application of the KeratinoSens™ assay for assessing the skin sensitization potential of agrochemical active ingredients and formulations.

Settivari RS, Gehen SC, Amado RA, Visconti NR, Boverhof DR, Carney EW.

Regul Toxicol Pharmacol. 2015 Jul;72(2):350-60. doi: 10.1016/j.yrtph.2015.05.006.

PMID:
25981449
3.

Relationships between pazopanib exposure and clinical safety and efficacy in patients with advanced renal cell carcinoma.

Suttle AB, Ball HA, Molimard M, Hutson TE, Carpenter C, Rajagopalan D, Lin Y, Swann S, Amado R, Pandite L.

Br J Cancer. 2014 Nov 11;111(10):1909-16. doi: 10.1038/bjc.2014.503. Erratum in: Br J Cancer. 2014 Dec 9;111(12):2383.

4.

Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials.

Tran HT, Liu Y, Zurita AJ, Lin Y, Baker-Neblett KL, Martin AM, Figlin RA, Hutson TE, Sternberg CN, Amado RG, Pandite LN, Heymach JV.

Lancet Oncol. 2012 Aug;13(8):827-37. doi: 10.1016/S1470-2045(12)70241-3.

PMID:
22759480
5.

Transarterial chemoembolization plus or minus intravenous bevacizumab in the treatment of hepatocellular cancer: a pilot study.

Britten CD, Gomes AS, Wainberg ZA, Elashoff D, Amado R, Xin Y, Busuttil RW, Slamon DJ, Finn RS.

BMC Cancer. 2012 Jan 14;12:16. doi: 10.1186/1471-2407-12-16.

6.

Predictive genomic biomarkers.

Kumar R, Amado RG.

Curr Top Microbiol Immunol. 2012;355:173-88. doi: 10.1007/82_2011_164. Review.

PMID:
21877260
7.

Triple-drug transcatheter arterial chemoembolization in unresectable hepatocellular carcinoma: assessment of survival in 124 consecutive patients.

Gomes AS, Rosove MH, Rosen PJ, Amado RG, Sayre JW, Monteleone PA, Busuttil RW.

AJR Am J Roentgenol. 2009 Dec;193(6):1665-71. doi: 10.2214/AJR.08.1806.

PMID:
19933662
8.

An open-label clinical trial evaluating safety and pharmacokinetics of two dosing schedules of panitumumab in patients with solid tumors.

Stephenson JJ, Gregory C, Burris H, Larson T, Verma U, Cohn A, Crawford J, Cohen RB, Martin J, Lum P, Yang X, Amado RG.

Clin Colorectal Cancer. 2009 Jan;8(1):29-37. doi: 10.3816/CCC.2009.n.005.

PMID:
19203894
9.

Association of progression-free survival, overall survival, and patient-reported outcomes by skin toxicity and KRAS status in patients receiving panitumumab monotherapy.

Peeters M, Siena S, Van Cutsem E, Sobrero A, Hendlisz A, Cascinu S, Kalofonos H, Devercelli G, Wolf M, Amado RG.

Cancer. 2009 Apr 1;115(7):1544-54. doi: 10.1002/cncr.24088.

10.

A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer.

Hecht JR, Mitchell E, Chidiac T, Scroggin C, Hagenstad C, Spigel D, Marshall J, Cohn A, McCollum D, Stella P, Deeter R, Shahin S, Amado RG.

J Clin Oncol. 2009 Feb 10;27(5):672-80. doi: 10.1200/JCO.2008.19.8135.

PMID:
19114685
11.

Association of K-ras mutational status and clinical outcomes in patients with metastatic colorectal cancer receiving panitumumab alone.

Freeman DJ, Juan T, Reiner M, Hecht JR, Meropol NJ, Berlin J, Mitchell E, Sarosi I, Radinsky R, Amado RG.

Clin Colorectal Cancer. 2008 May;7(3):184-90. doi: 10.3816/CCC.2008.n.024.

PMID:
18621636
12.

Targeting vascular endothelial growth factor with the monoclonal antibody bevacizumab inhibits human hepatocellular carcinoma cells growing in an orthotopic mouse model.

Finn RS, Bentley G, Britten CD, Amado R, Busuttil RW.

Liver Int. 2009 Feb;29(2):284-90. doi: 10.1111/j.1478-3231.2008.01762.x.

PMID:
18482274
13.

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.

Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, Juan T, Sikorski R, Suggs S, Radinsky R, Patterson SD, Chang DD.

J Clin Oncol. 2008 Apr 1;26(10):1626-34. doi: 10.1200/JCO.2007.14.7116.

PMID:
18316791
14.

Dose and schedule study of panitumumab monotherapy in patients with advanced solid malignancies.

Weiner LM, Belldegrun AS, Crawford J, Tolcher AW, Lockbaum P, Arends RH, Navale L, Amado RG, Schwab G, Figlin RA.

Clin Cancer Res. 2008 Jan 15;14(2):502-8. doi: 10.1158/1078-0432.CCR-07-1509.

15.

Association of progression-free survival with patient-reported outcomes and survival: results from a randomised phase 3 trial of panitumumab.

Siena S, Peeters M, Van Cutsem E, Humblet Y, Conte P, Bajetta E, Comandini D, Bodoky G, Van Hazel G, Salek T, Wolf M, Devercelli G, Woolley M, Amado RG.

Br J Cancer. 2007 Dec 3;97(11):1469-74.

16.

Influence of roasting conditions on the acrylamide content and the color of roasted almonds.

Lukac H, Amrein TM, Perren R, Conde-Petit B, Amadò R, Escher F.

J Food Sci. 2007 Jan;72(1):C033-8.

PMID:
17995869
17.

From XenoMouse technology to panitumumab, the first fully human antibody product from transgenic mice.

Jakobovits A, Amado RG, Yang X, Roskos L, Schwab G.

Nat Biotechnol. 2007 Oct;25(10):1134-43.

PMID:
17921999
18.

Occurrence of acrylamide in selected foods and mitigation options.

Amrein TM, Andres L, Escher F, Amadò R.

Food Addit Contam. 2007;24 Suppl 1:13-25. Review.

PMID:
17687696
19.

An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy.

Van Cutsem E, Siena S, Humblet Y, Canon JL, Maurel J, Bajetta E, Neyns B, Kotasek D, Santoro A, Scheithauer W, Spadafora S, Amado RG, Hogan N, Peeters M.

Ann Oncol. 2008 Jan;19(1):92-8.

PMID:
17785764
20.

Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer.

Hecht JR, Patnaik A, Berlin J, Venook A, Malik I, Tchekmedyian S, Navale L, Amado RG, Meropol NJ.

Cancer. 2007 Sep 1;110(5):980-8.

Items per page

Supplemental Content

Support Center